Overview
Pseudobulbar affect (PBA) is a condition that's characterized by episodes of sudden uncontrollable and inappropriate laughing or crying. PBA typically occurs in people with certain neurological conditions or injuries, which might affect the way the brain controls emotion.

Nuedexta® (dextromethorphan hydrobromide/quinidine sulfate) is a combination product containing dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 agonist) and quinidine sulfate (a CYP450 2D6 inhibitor) indicated for the treatment of Pseudobulbar affect (PBA).

Coverage Guidelines
Authorization may be granted for members with a diagnosis or indication for the treatment of Pseudobulbar Affect (PBA) due to a neurological condition (e.g., amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), stroke, traumatic brain injury, Alzheimer’s disease, Parkinson’s disease).

Limitations
1. Initial approvals will be for 12 months.
2. A quantity limit of 60 capsules per month applies.

References


**Review History**
11/28/11 – Reviewed
01/03/12 – Effective
11/26/12 – Reviewed
12/01/12 – Updated (RxAuth implementation)
11/25/13 – Reviewed
11/24/14 – Reviewed
11/27/17 – Reviewed in P&T Meeting
11/26/18 – Updated

**Disclaimer**
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.